Onyx Biotec open offer acquires 5.06 lakh shares at Rs 36.50
Key highlights
- Onyx Biotec’s open offer acquired 5,06,000 shares at Rs. 36.50 per share.
- The acquired shares imply consideration of about Rs. 1.85 crore.
- The Bhardwaj acquirers and persons acting in concert hold 41.83% after tendering.
- The offer sought up to 47,14,372 shares, equal to 26.00% of fully diluted voting capital.
powered by IRIS

Onyx Biotec Limited’s open offer acquired 5,06,000 shares at Rs. 36.50 each, with the Bhardwaj acquirers and persons acting in concert holding 41.83% after the tendering process. The result follows an offer for up to 47,14,372 shares, representing 26% of Onyx Biotec’s fully diluted paid-up equity and voting capital.
Know Onyx Biotec inside out
Results, valuation, peers and who's buying, in one view.
What was the outcome of Onyx Biotec’s open offer?
Onyx Biotec’s post-tendering update states that 5,06,000 shares were acquired through the open offer at Rs. 36.50 per share. Based on the disclosed share count and price, the acquired shares represent consideration of about Rs. 1.85 crore.
The offer was made by Kunal Bhardwaj, Gautam Bhardwaj, Kanhaiya Bhardwaj and Kapil Bhardwaj. VC Corporate Advisors Private Limited acted as manager to the offer, while MAS Services Limited was appointed as registrar.
The acquirers and persons acting in concert now hold 41.83% of Onyx Biotec, according to the post-tendering disclosure. The update indicates that the tendering stage has concluded and the offer has moved into the post-offer disclosure process.
The announcement submitted to the National Stock Exchange refers to a post-offer advertisement. Such filings communicate the status of the offer to public shareholders after the tendering period and are part of the process prescribed under the SEBI takeover regulations.
What were the terms and timeline of the offer?
The offer sought to acquire up to 47,14,372 fully paid-up equity shares of face value Rs. 10 each at a fixed cash price of Rs. 36.50 per share. The maximum offer size represented 26.00% of Onyx Biotec’s total paid-up equity and voting share capital on a fully diluted basis.
The tendering period opened on October 13, 2026, and closed on October 27, 2026. The schedule stated that communication of acceptance or rejection and payment of consideration for accepted applications would be completed by November 11, 2026.
The offer documents were issued under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The process began with a public announcement dated July 24, 2026, followed by a corrigendum, detailed public statement, draft letter of offer and letter of offer.
Got a follow-up? Ask IRIS
How did the Onyx Biotec offer process unfold?
The Onyx Biotec offer process started with the public announcement on July 24, 2026. A corrigendum to the public announcement followed on July 30, and the detailed public statement was published on July 31.
VC Corporate Advisors filed the draft letter of offer on August 7. The letter of offer is listed among the company’s takeover-related filings, and the offer-opening public announcement was issued on October 12, ahead of the October 13 commencement of tendering.
The company’s committee of independent directors issued its recommendation on October 7, according to the disclosed event schedule. The materials also specified that the offer was a takeover offer, with Onyx Biotec listed on the NSE Emerge platform.
A corrigendum to the letter of offer was subsequently filed by VC Corporate Advisors. Investors evaluating the transaction can refer to the public announcement, detailed public statement, letter of offer and post-offer advertisement made available through NSE and SEBI disclosures.
Why does the 41.83% holding matter to investors?
The reported 41.83% holding is relevant because it quantifies the acquirers’ ownership after the tendering process. The offer was designed to allow the acquirers to purchase up to 26% of the company’s fully diluted share capital, but the reported acquisition was 5,06,000 shares against the stated maximum of 47,14,372 shares.
The difference between the maximum offer size and shares acquired shows the number of shares tendered and accepted under the offer was lower than the maximum quantity sought. The disclosed facts do not provide a reason for the level of participation, and investors should not infer one without further company or exchange disclosures.
For shareholders, the Rs. 36.50 offer price was the fixed cash price available during the tendering window. The documents also set the market lot at 2,000 equity shares and identify the shares as having a face value of Rs. 10 each.
The filing does not itself provide a revised business strategy, board change, financial forecast or operational plan for Onyx Biotec. Its primary importance is the formal reporting of the open-offer result and the ownership position disclosed after tendering.
Conclusion
Onyx Biotec’s open offer has reached the post-tendering stage, with 5,06,000 shares acquired at Rs. 36.50 each and the Bhardwaj acquirers and persons acting in concert reported to hold 41.83%. The transaction was conducted through the SEBI takeover framework and had sought up to 47,14,372 shares, or 26% of the company’s fully diluted voting capital.
Investors should watch for the post-offer advertisement and any subsequent NSE or company disclosures that clarify the final settlement of accepted shares and the ownership structure. The disclosed schedule set November 11, 2026, as the date for communicating acceptance or rejection and paying consideration for accepted tender applications.


